ALLMedicine™ Lennox-gastaut Syndrome Center

Jun 21st, 2022 - The drug being tested in this study is called soticlestat (TAK-935). Soticlestat will be assessed for efficacy, safety, and tolerability in pediatric and adult participants with Lennox-Gastaut syndrome (LGS). The study will enroll approximately 23...

Jun 7th, 2022 - Background and Significance of the Proposed Project The COVID-19 pandemic has hit us like a ton of bricks creating unimaginable levels of unanticipated death, financial hardship, and dramatic changes in nearly every facet of our life including sch...

Jun 1st, 2022 - De novo truncating mutations of AHDC1 gene cause Xia-Gibbs Syndrome (XGS), characterized by developmental delay, hypotonia, speech disturbances, sleep apnea. Seizures have been reported, yet no studies have depicted the epilepsy characteristics an...

May 23rd, 2022 - The secondary objectives are: To evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the total number of seizures compared with placebo in pediatric and adult subjects diagnosed with Lennox Gastaut Syndrome (LGS) Asse...

May 16th, 2022 - Subjects who successfully completed the YKP509C001 study and could benefit from continued exposure to carisbamate. This is an open-label (OL), multi-center study of carisbamate in subjects with LGS, with safety assessments from Baseline (Visit 1) ...

Jun 21st, 2022 - The drug being tested in this study is called soticlestat (TAK-935). Soticlestat will be assessed for efficacy, safety, and tolerability in pediatric and adult participants with Lennox-Gastaut syndrome (LGS). The study will enroll approximately 23...

Jun 7th, 2022 - Background and Significance of the Proposed Project The COVID-19 pandemic has hit us like a ton of bricks creating unimaginable levels of unanticipated death, financial hardship, and dramatic changes in nearly every facet of our life including sch...

May 23rd, 2022 - The secondary objectives are: To evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the total number of seizures compared with placebo in pediatric and adult subjects diagnosed with Lennox Gastaut Syndrome (LGS) Asse...

May 16th, 2022 - Subjects who successfully completed the YKP509C001 study and could benefit from continued exposure to carisbamate. This is an open-label (OL), multi-center study of carisbamate in subjects with LGS, with safety assessments from Baseline (Visit 1) ...

May 16th, 2022 - Background and Significance: Lennox-Gastaut Syndrome (LGS) is a rare developmental-epileptic encephalopathy characterized by life-long refractory seizures which result in frequent utilization of emergency healthcare resources and also contribute t...

May 5th, 2022 - A daily dose of fenfluramine (Fintepla, UCB), when added to an existing anti-epileptic treatment regimen, significantly reduced the frequency of drop seizures associated with Lennox-Gastaut syndrome (LGS) in the phase 3 study that led to US approv...

May 3rd, 2022 - Menopause status moderated sex differences in tau burden, with a divergence in tauopathy between the sexes apparent 20 years earlier than previously reported. (Annals of Neurology) Plasma p-tau was a less consistent marker of brain amyloidosis in ...

Mar 29th, 2022 - Higher levels of moderate-to-vigorous physical activity were tied to a lower risk for disabling dementia in Japanese men. (JAMA Network Open) At current expected prices, neither aducanumab (Aduhelm) nor donanemab, an investigational anti-amyloid d...

Mar 29th, 2022 - The US Food and Drug Administration (FDA) has approved fenfluramine (Fintepla) oral solution, a Schedule IV controlled substance, for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children aged 2 years and older, the c...

Oct 13th, 2021 - Children and young adults with epilepsy had fewer seizures after combination treatment with the drug Epidiolex, which contains the cannabidiol (CBD), and various doses of tetrahydrocannabinol (THC), the component of cannabis that makes people high.